Regional anaesthesia and anticoagulation.
As the life expectancy of our Western population progressively increases, so does the prevalence of cardiovascular disease and thus the use of antithrombotic drugs. The use of central neuraxial anaesthesia techniques in patients treated with these drugs is a major clinical problem as the presence of an impaired coagulation has been found to be the most important risk factor contributing to the formation of a spinal haematoma. The growing number of case reports of spinal haematoma has led many national societies of anaesthetists to come up with guidelines. This article presents an overview of current guidelines on the use of regional anaesthetic techniques in patients treated with various anticoagulants and also describes a possible strategy to deal with new antithrombotic drugs that have recently been introduced in some countries or will be shortly in others.
Vandermeulen
Erik
E
Department of Anaesthesiology, University Hospitals Leuven, Katholieke Universiteit Leuven, Herestraat 49, B-3000 Leuven, Belgium. erik.vandermeulen@uzleuven.be
D000765:Anesthesia, Conduction; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000517:prevention & control*; D017408:Guidelines as Topic; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007431:Intraoperative Complications / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D013917:Thrombin